Tau-Targeting Approach Put to Test in TauRx's Phase III
LONDON – TauRx Therapeutics Ltd. said it has recruited the first patients to two Phase III Alzheimer's disease trials in which it aims to provide the first definitive proof that breaking down tangles of tau protein in the brain has a disease-modifying effect in the mild to moderate stages of pathology.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter